+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.

Age: 18Years +All GendersPhase 3
112 locations
E

Actively Recruiting

Researchers are conducting a multicenter, prospective observational study to evaluate how well artificial intelligence AI models based on pre-treatment dynamic contrast-enhanced MRI DCE-MRI scans predict the benefit of neoadjuvant chemotherapy in women with locally advanced triple-negative breast cancer. The study aims to categorize patients into high-benefit and low-benefit groups using this AI model to better understand chemotherapy responsiveness. Participants will receive routine standard neoadjuvant chemotherapy as part of their care. Before chemotherapy, all patients will undergo a DCE-MRI scan, and the AI model will analyze these images to classify their expected benefit from chemotherapy. The study collects clinical data, chemotherapy regimens, and treatment outcomes, including whether the cancer completely responds to therapy, to compare these results within AI-defined subgroups. Throughout the study, participants will provide baseline clinical-pathological information, MRI scans, and biopsy samples. Researchers will monitor treatment response through pathological complete response pCR rates, objective response rates ORR, and long-term outcomes such as disease-free survival DFS and overall survival OS for up to five years. The primary measure is the rate of complete cancer response after chemotherapy and surgery, with secondary analyses evaluating differences between high- and low-benefit groups.

Age: 18Years +FEMALE
5 locations
A

Actively Recruiting

Researchers are conducting a multicenter, prospective observational study to evaluate how well artificial intelligence AI models using pre-treatment dynamic contrast-enhanced MRI DCE-MRI can predict the benefit of neoadjuvant chemotherapy in women with hormone receptor-positive, HER2-negative HRHER2- breast cancer. The study aims to stratify patients into groups with high or low expected benefit from chemotherapy and assess outcomes such as residual cancer burden and long-term survival. Participants receive routine standard neoadjuvant chemotherapy and undergo pre-treatment breast DCE-MRI scans. The AI model analyzes these images to categorize patients into high-benefit or low-benefit subgroups. Data collected include baseline clinical and pathological information, chemotherapy regimens, and post-surgery residual cancer classifications. The study evaluates response rates and survival outcomes up to five years after surgery. During the study, participants provide clinical data and imaging before starting chemotherapy. After treatment and surgery, researchers measure residual cancer burden and objective tumor response. Long-term follow-up tracks disease-free and overall survival for up to 60 months. The main outcome is the rate of minimal residual cancer after chemotherapy, helping to verify the AI models usefulness for individualized treatment selection in this breast cancer population.

Age: 18Years +FEMALE
5 locations